

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189

SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an “Intention to grant” for SynAct’s patent application covering the company’s leading drug candidate AP1189 in methods of treating kidney diseases.

SynAct has received information that the company obtained an “Intention to grant” from the EPO regarding their patent application 19734023.5 (EP publication 3743064) which concerns the use of AP1189 in methods of treating kidney disease, specifically primary nephrotic syndrome, including membranous nephropathy as is currently tested in clinical trials.

In brief, an “Intention to grant” means that the EPO intends to grant a European patent on the basis of the patent application as currently on file. Before a final decision to grant can be issued by the EPO further formalities must be adhered to.

“We are very excited about this development. It is an important step forward in the further reinforcement of a strong and robust patent portfolio for our lead drug candidate AP1189, which is now in a number of clinical studies for different indications with great unmet medical need,” said SynAct’s CSO Thomas Jonassen.

The information was submitted, through the agency of the contact person below, for publication on April 13, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: joo@synactpharma.com

Thomas Jonassen

CSO, SynAct Pharma AB

Phone: +45 40 15 66 69

Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.

About AP1189

The mechanism of action of SynAct Pharma’s lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388). This effect has shown to be effective in disease models of inflammatory and autoinflammatory diseases and the clinical potential of the approach is currently tested in a clinical phase 2 study in patient with active Rheumatoid Arthritis.

<https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1>).